Panel Discussion: Didactic Session 6: Advanced Disease

Dr. William K. Oh is Chief Medical Officer at the Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to the eradication of prostate cancer and is also a Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers.

Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston. Dr. Oh completed a fellowship in medical oncology at the Dana-Farber Cancer Institute.

For two years prior to joining PCF, Dr. Oh was the Chief Medical Officer at Sema4, a patient-centered health intelligence company. From 2009-2020, Dr. Oh was Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at Mount Sinai. Dr. Oh spent 14 years at Harvard Medical School and the Dana-Farber Cancer Institute in Boston, including service as Clinical Director of GU Oncology and Associate Professor of Medicine.

Dr. Oh has authored more than 350 original articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), and the American Urological Association (AUA), including the Guidelines Committee for Castration-Resistant Prostate Cancer. In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors, and Super Doctors.

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope.

Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Dr. Sartor earned his MD from Tulane University School of Medicine in 1982. After training at the University of Pennsylvania and Tulane Medical School, he completed a fellowship at the National Cancer Institute, where he focused on advanced prostate cancer therapies. He held positions at LSU Medical School and LSU Health Sciences Center, directing oncology programs before joining Dana Farber Cancer Institute in 2006. In 2008, he returned to Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research.

An internationally recognized expert in prostate cancer, Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.

Having published over 500 scholarly articles and having served as the past Chairman of the Department of Defense Prostate Integration Panel, Dr. Sartor, in addition to being the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology, is the Medical Oncology Chair of the GU Committee of the NRG, the Assistant Dean for Oncology at Tulane University School of Medicine, the Medical Director of the Tulane Cancer Center, and the Editor-in-Chief of the peer-reviewed journal, Clinical Genitourinary Cancer. In addition, he is currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).

James A. Eastham, MD, FACS, is the Peter T. Scardino Chair in Oncology and Chief of the Urology Service in the Department of Surgery at Memorial Sloan-Kettering Cancer Center in New York. Dr. Eastham received his medical degree from the University of Southern California, Los Angeles. He completed an Internship in General Surgery and a Residency in Urology at Los Angeles County+USC Medical Center. He went on to complete a Fellowship in Urologic Oncology at Baylor College of Medicine in Houston, Texas. Prior to his appointment at Memorial Sloan-Kettering Cancer Center, Dr. Eastham was an Assistant and Associate Professor in the Department of Urology at Louisiana State University in Shreveport and Chief of Urology at Overton-Brooks Veterans Administration Medical Center in Louisiana.

Dr. Eastham’s research has focused on the prevention and treatment of prostate cancer, and he has a particular interest in improving oncologic and quality-of-life outcomes after radical prostatectomy. He has authored or co-authored over 300 articles which have appeared in peer-reviewed journals such as the Journal of the American Medical Association, the Journal of Urology, the Journal of Clinical Oncology, Urology, and Transplantation. In addition, he has authored numerous book chapters, reviews, monographs, and abstracts. He is a Fellow of the American College of Surgeons and a member of several professional societies, including the American Urologic Association, the Society of Urologic Oncology, and the Societé Internationale D’Urologie.

Juanita M. Crook, MD, FRCPC, completed her medical training at the University of Toronto and her Residency in Radiation Oncology at Princess Margaret Hospital. She is currently a Professor of Radiation Oncology at the University of British Columbia in Kelowna. She is a radiation oncologist at the BC Cancer Agency Sindi Ahluwalia Hawkins Centre for the Southern Interior, also in Kelowna, where she has developed image-guided HDR gynecologic brachytherapy, US-planned HDR prostate brachytherapy, and permanent seed brachytherapy for breast cancer.

Previously a Professor of Radiation Oncology at the University of Toronto/University Health Network and Associate Professor at the University of Ottawa, she has a particular interest in intermittent androgen suppression, post-radiation prostate biopsies, and penile brachytherapy. She has written more than 20 book chapters and over 200 journal articles and is a frequent speaker at international meetings where she presents in English, French, and Spanish. She was Scientific Chair of the 2007 American Brachytherapy Society meeting and frequently teaches at the ABS Prostate Brachytherapy School. She is the Former President of the Board of the American Brachytherapy Society and the recipient of the Thom Shanahan Distinguished Brachytherapy Educator Award.